GLP-1 agonists like Ozempic and Wegovy are a pharma industry dream: mega-blockbuster products that are visibly transforming patient outcomes, particularly now in the context of treating obesity.
But they also present an operational nightmare for companies, as volumes of adverse events overwhelm traditional safety workflows.
Glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic and Wegovy now account for more than 7% of all prescriptions in the US, reflecting their rapid adoption beyond diabetes care – particularly in weight management.
Check out the rest of the feature here
